Abstract
Background
Natural killer (NK)-like T cells comprising CD56+ T cells and CD57+ T cells belong to a subset of CD1d-independent NKT cells playing an important role in regulating immune responses. Although NK-like T cells are reported to increase in patients with advanced gastric carcinomas, it remains unknown how NK-like T cells are involved in disease progression in gastric cancer patients.
Methods
The proportions of Th1 cells (interferon [IFN]-γ-producing CD4+ T cells), Th2 cells (IL-4-producing CD4+ T cells), and NK-like T cells (CD56+ T cells and CD57+ T cells) in the peripheral blood of 48 gastric cancer patients and 20 healthy controls were measured by two-color flow cytometry analysis and by intracellular cytokine analysis to investigate an association of these immune cells with the survival rate of gastric cancer patients.
Results
Univariate analysis showed that Th1 cells and CD57+ T cells, as well as some clinicopathological factors, significantly influenced the survival rate. CD57-high (≧18%) patients survived for a significantly shorter period after surgery compared to CD57-low patients (P = 0.046; Kaplan-Meier, log-rank test) in the stage III–IV patients, but not in the stage I–II patients. Further, multivariate analysis showed that lymphatic invasion was a statistically significant independent risk factor in all the gastric cancer patients, but the proportion of CD57+ T cells as well as depth of tumor were statistically significant independent risk factors in patients with advanced carcinomas (stage III–IV).
Conclusion
An increased proportion (≧18%) of CD57+ T cells in the peripheral blood of patients with advanced gastric carcinomas could indicate a poor prognosis.
Similar content being viewed by others
References
Takii Y, Hashimoto S, Iiai T, et al. (1994) Increase in the proportion of granulated CD56+ T cells in patients with malignancy. Clin Exp Immunol 97:522–527
Okada T, Iiai T, Kawachi Y, et al. (1995) Origin of CD8+CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 102:159–166
Matsuda JL, Gapin L, Fazilleau N, et al. (2001) Natural killer T cells reactive to a single glycolipid exhibit a highly diverse T cell receptor β repertoire and small clone size. Proc Natl Acad Sci U S A 98; 12636–12641
Wajchman HJ, Pierce CW, Varma VA, et al. (2004) Ex vivo expansion of CD8+CD56+ and CD8+CD56-natural killer T cells specific for MUC1 mucin. Cancer Res 64:1171–1180
Baxevanis CN, Gritzapis AD, Tsitsilois OE, et al. (2002) HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 20: 864–872
Pittet MJ, Speiser DE, Valmori D, et al. (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148–1152
Lu PH, Negrin RS (1995) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687–1696
Satoh M, Seki S, Hashimoto W, et al. (1996) Cytotoxic γδ or αβ T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 157:3886–3892
Izquierdo M, Balboa MA, Fernandez-Ranada JM, et al. (1990) Relation between the increase of circulating CD3+CD57+ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation. Clin Exp Immunol 82:145–150
Hilbe W, Eisterer W, Schmid C (1994) Bone marrow lymphocytes subsets in myelodysplastic syndromes. J Clin Pathol 47: 505–507
Gorochov G, Debre P, Leblond V, et al. (1994) Oligoclonal expansion of CD8+CD8+CD57+ T cells with restricted T-cell receptor β chain variability after bone marrow transplantation. Blood 83: 587–595
Fregona I, Guttmann RD, Jean R (1985) HNK-1+ (Leu-7) and other lymphocytes subsets in long-term survivors with renal allotransplants. Transplantation 39:25–29
Arai K, Yamamura S, Seki S, et al. (1998) Increase of CD8+CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role. Clin Exp Immunol 111:345–352
Dupuy d’Angeac A, Monier S, Jorgensen C (1993) Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease. Arthritis Rheum 36:608–612
Legac E, Autran B, Merie-Beral H, et al. (1992) CD4+CD7-CD8+CD57+ T cells:a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood 79: 1746–1753
Sadat-Sowti B, Debre P, Mollet L, et al. (1994) An inhibitor of cytotoxic functions produced by CD8+CD57+ T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur J Immunol 24:2882–2888
Koyama S, Ebihara T, Fukao K (1992) Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 118:609–614
Karimine N, Nanbara S, Arinaa S, et al. (1994) Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. J Surg Oncol 66:179–185
Arinaga S, Karimine N, Nanbara S, et al. (1995) Lymphokine-activated killer cell function of lymphocytes from regional lymph nodes in patients with gastric carcinoma. J Surg Oncol 58:44–49
Mosmann TR, Cherwinski H, Bond MW, et al. (1986) Two types of murine helper cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348–2357
Trinchieri G (1995) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cytotoxic lymphocytes. Blood 84: 4008–4027
Nishimura T, Watanabe K, Lee U, et al. (1995) Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor. Immunol Lett 48:149–152
Tahara H, Zer HZ, Storkus WJ, et al. (1994) Fibroblast genetically engineered to express IL-12 can suppress tumor growth and induce antitumor immunity to murine melanoma cell lines. Cancer Res 54:182–189
Fujiwara H, Clark SC, Hamaoka T (1996) Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann NY Acad Sci 795:294–309
Elsasser-Beile U, Kokble N, Grussenmeyer T, et al. (1998) Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol 19:470–476
Ren Z, Pang G, Clancy R, et al. (2001) Shift of the gastric T-cell response in gastric carcinoma. J Gastroenterol Hepatol 16: 142–148
Tabata T, Hazama S, Yoshino S, Oka M (1999) Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg 177:203–208
Nakayama H, Kitayama J, Muto T, Nagawa H (2000) Characterization of intracellular cytokine profile of CD4 (+) T cells in peripheral blood and tumor draining lymph nodes of patients with gastrointestinal cancer. Jpn J Clin Oncol 30:301–305
Goto S, Sato M, Kaneko R, et al. (1999) Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 48:435–442
Sato M, Goto S, Kaneko R, et al. (1998) Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 18:3951–3955
Pellegrini P, Berghella AM, Del Beato T, et al. (1996) Disregulation in Th1 and Th2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1–8
Arase H, Arase N, Nakagawa K, et al. (1993) NK1.1+ CD4+CD8-thymocytes with specific lymphokine secretion. Eur J Immunol 23:307–310
Arase H, Arase N, Saito T (1996) Interferon gamma production by natural killer (NK) cells and NK 1.1 T cells upon NKR-P1 cross-linking. J Exp Med 183:2391–2396
Kennedy B. The unified international gastric cancer staging classification. Scand J Gastroenterol 1987;22:11–13
Sobin LH, Wittekind CH (1997) UICC TNM Classification of malignant tumours. John Wiley and Sons, New York
Picker LJ, Singh MK, Zdraveski Z, et al. (1995) Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86:1408–1419
Divine M, Lecouedic JP, Gourdin MF, et al. (1988) Functional analysis of CD8 lymphocytes in long-term surviving patients after bone marrow transplantation. J Clin Immunol 8:140–147
Ohkawa T, Seki S, Dobashi H (2001) Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 103:281–290
Sadat-Sowti B, Debre P, Idziorek T, et al. (1991) A lectin-binding soluble factor released by CD8+CD57+ lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol 21:737–741
Leroy E, Calvo CF, Divine M, et al. (1986) Persistence of T8+/HNK-1+ suppressor lymphocytes in the blood of long-term surviving patients after allongeneic bone marrow transplantation. J Immunol 137:2180–2189
Landay A, Larry-Gartland G, Clement LT (1983) Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol 131: 2757–2761
Clement LT, Grossi CE, Larry-Gartland G (1984) Morphologic and phenotypic features of the subpopulation of Leu2+ cells that suppresses B cell differentiation. J Immunol 133:2461–2468
Halwani F, Guttman RD, Ste-Croix H, Prud’homme GJ (1992) Identification of natural suppressor cells in long-term renal allograft recipients. Transplantation 54:973–977
Joly P, Guillon J-M, Mayud C, et al. (1989) Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol 143: 2193–2201
Autran B, Leblond V, Sadat-Sowti B, et al. (1991) A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood 77: 2237–2241
Mollet L, Sadat-Sowti B, Duntze J, et al. (1998) CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 10:311–323
Frassanito MA, Silvestris F, Cafforio P, Dommacco F (1998) CD8+/CD57 cells and apoptosis suppress T-cell functions in multiple myeloma. Br J Haematol 100:469–477
Sze DM, Giesajitis G, Brown RD, et al. (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+ CD28-compartment. Blood 98:2817–2827
Chochi K, Ichikura T, Majaima T, et al. (2003) The increase of CD8+CD57+ T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer. Oncol Rep 20:2443–2448
Characiejus D, Pasukoniene V, Kazlauskaite K, et al. (2002) Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22:3679–3684
Ishigami S, Natsugoe S, Tokuda K (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88:577–583
Villegas FR, Coca S, Villarrubia VG (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35:23–28
Reipert B, Scheuch CH, Lukowsky A, et al. (1992) CD3+CD56+ lymphocytes are not likely to be involved in antigen-specific rejection processes in long-term allograft recipients. Clin Exp Immunol 89:143–147
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Akagi, J., Baba, H. Prognostic value of CD57+ T lymphocytes in the peripheral blood of patients with advanced gastric cancer. Int J Clin Oncol 13, 528–535 (2008). https://doi.org/10.1007/s10147-008-0789-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-008-0789-8